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Background and purpose: There are a few retrospective subgroup analyses or registries of large-vessel
(≥3.5mm) stenting.We investigated clinical outcomes of patientswith ST-segment elevationmyocardial
infarction (STEMI) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES)
and bare-metal stents (BMS) in large coronary vessels.
Methods and subjects: Of 1100 STEMI patients registered in the Ibaraki Cardiovascular Assessment Study
(ICAS) multicenter registry from April 2007 to June 2012 who underwent PCI, we enrolled 454 patients
(65.8±12.7 years old, 81% male) with ≥3.5-mm stents. We excluded 53 patients with cardiogenic shock
or left main trunk lesions. The remaining 401 patients were divided into Group-D, PCI with DES (n=184),
and Group-B, PCI with BMS (n=217). Propensity score analysis matched 1:1 according to treatment with
DES (n=101) or with BMS (n=101). We evaluated major adverse cardiac and cerebrovascular events
(MACCE) and incidence of stent thrombosis (ST). MACCE was deﬁned as all-cause death, myocardial
infarction (MI), target-vessel revascularization (TVR), or cerebrovascular accident (CVA).
Essential results: During a mean follow-up period of 526 days, all-cause death, MI, CVA, MACCE, and ST
were not signiﬁcantly different in Group-D versus Group-B (all-cause death: 4.35% vs. 4.61%, p=0.90; MI:
0% vs. 0%; CVA: 2.72% vs. 3.23%, p=0.76; MACCE: 15.2% vs. 20.3%, p=0.19; and ST: 0.0% vs. 1.38%, p=0.11).
After adjusting for age, insulin use,multivessel disease, intra-aortic balloon pumpuse, culprit lesions, and
2estimated glomerular ﬁltration rate <60ml/min/1.73m , MACCE was not signiﬁcantly different between
thegroups (odds ratio:0.69;95%CI: 0.40–1.23;p=0.21).However, TVRwas signiﬁcantly lower inGroup-D
than Group-B in Kaplan–Meier analysis (p=0.048) after propensity score matching.
Principal conclusion:Therewasnoadvantage tousing aDES in largevessels for preventing ahardendpoint,
whereas DES use resulted in a signiﬁcant reduction in TVR in the patients with STEMI in this registry.
© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.ntroductionPercutaneous coronary intervention (PCI) is the ideal reper-
usion tactic for patients with ST-segment elevation myocardial
∗ Corresponding author at: Cardiovascular Division, Faculty of Medicine, Univer-
ity of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575,
apan. Tel.: +81 29 853 3143; fax: +81 29 853 3143.
E-mail address: asato@md.tsukuba.ac.jp (A. Sato).
ttp://dx.doi.org/10.1016/j.jjcc.2014.02.020
914-5087/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reinfarction (STEMI) [1–3]. Drug-eluting stents (DES) have reduced
the rate of restenosis as compared with bare-metal stents (BMS).
However, for patients with stenoses in large coronary arteries, the
beneﬁt of the use of DES has been considered uncertain. “Bigger is
better” was the catchphrase in the BMS era. Elezi et al. and oth-
ers reported that patients with small vessels present a higher risk
for an adverse outcome after coronary stent placement because
of a higher incidence of restenosis [4,5]. In contrast, no signiﬁcant
reduction in the rate of target-vessel revascularization (TVR) was
found in the BASKET sub-study among patients with stenoses in
served.
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arge coronary arteries who received DES and those who received
MS [6,7]. Kaiser et al. reported that in patients requiring stenting
f large coronary arteries (≥3.0mm), there were no signiﬁcant dif-
erences in the rates of death or myocardial infarction (MI) among
atients with sirolimus-eluting stents (SES), everolimus-eluting
tents (EES), and BMS [8]. In contrast, in small-vessel stenting, the
articular beneﬁt of DES has been shown repeatedly [9–15]. Fur-
hermore, the risk of late stent thrombosis has been shown for
ES, as premature discontinuation of dual antiplatelet therapy is
major risk factor [16,17]. There have been a few retrospective
ubgroup analyses or registries of large vessel stenting (≥3.5mm)
18,19]. Although it is difﬁcult to know the patient’s background
n the setting of acute coronary syndrome, the interventional car-
iologist nevertheless needs to choose the stent immediately. It
s unclear whether DES or BMS should be used in large ves-
els (deﬁned as those with a diameter of ≥3.5mm) of Japanese
atients with STEMI. Therefore, the aim of this study was to inves-
igate the clinical outcomes of Japanese patients with STEMI who
nderwent PCI with DES and BMS implantation in large coronary
essels.
aterials and methods
Written informed consent was obtained from all patients, and
ata collection for this study was approved by each institution’s
eview board. The Ibaraki Cardiovascular Assessment Study (ICAS)
as a multicenter registry involving 12 hospitals in Ibaraki Pre-
ecture, Japan. The present study population consisted of 1100
onsecutive patients with STEMI treated with primary PCI at all
nstitutions in the ICAS registry from April 2007 to June 2012 who
eceived a stent. Among these patients, a total of 454 consecu-
ive STEMI patients who were treated with a stent of 3.5mm or
ore in diameterwere enrolled. Of these 454patients,we excluded
3 patients classiﬁed as Killip class IV or with left main
runk lesion, and thus we examined clinical outcomes of
01 STEMI patients inwhoma ≥70% diameter stenosiswas present
n the epicardial coronary arteries or their major branches by
isual estimation. Inclusion criteria for the STEMI patients were
1) chest pain of >30min in duration and presentation to hospi-
al within 12h after onset of symptoms; (2) ST-segment elevation
f >0.1mV in two contiguous electrocardiographic leads; and (3)
levated creatine kinase MB isoenzymes within 12h of chest pain.
mong the 401 patients, the BMS group (Group-B) included 217
54.1%) patients, and theDESgroup (Group-D) included184 (45.9%)
atients (Fig. 1). Of the 184 patients who received DES, 47.8% of the
tents were ﬁrst-generation DES (SES or paclitaxel-eluting stent),
nd 52.2% were second-generation DES (zotarolimus-eluting stent,
ES, or biolimus-eluting stent).
BMS group
(N=217)
DES group
(N=184)
.
.
<3.5-mm stent implanted in paents
53 paents with cardiogenic shock or LMT lesion
454 STEMI paents underwent PCI with ≥3.5-mm stent
401 paents (65.2±12.8 years old, 85% male)
1100 STEMI paents underwent PCI in the ICAS registry 
ig. 1. Study cohort. BMS, bare-metal stent; DES, drug-eluting stent; ICAS, Ibaraki
ardiovascular Assessment Study; LMT, leftmain trunk; PCI, percutaneous coronary
ntervention; STEMI, ST-segment elevation myocardial infarction.logy 64 (2014) 377–383
Experienced interventional cardiologists performed coronary
angiography through the femoral approach with 6F catheters. The
culprit coronary artery was deﬁned on the basis of electrocardio-
graphy and angiographic results. All the patients undergoing initial
PCI were treated with both aspirin and a 300-mg loading dose of
clopidogrel. The contrast agent used was iopamidol (370mg I/ml;
Schering, Berlin, Germany). Postprocedural optimal coronary ﬂow
was deﬁned as a Thrombolysis in Myocardial Infarction (TIMI) ﬂow
grade of ≥3 and no residual stenosis (less than 10%). Incomplete
reperfusion or lack of procedural success was deﬁned as TIMI ﬂow
0–2 [20]. Time to reperfusionwasdeﬁnedas theperiod fromtimeof
onset of symptoms to the time of reperfusion. The standard of care
at discharge was to prescribe clopidogrel for 1 year to all patients
treated with DES, whereas clopidogrel was prescribed for at least
3 months to patients treated with BMS. All the patients underwent
clinical follow-up at 30 days, 6 months, and 1 year as an outpatient,
and follow-up angiography was also performed at 6–12 months
after PCI.
Clinical endpoints were deﬁned as in-hospital death and major
adverse cardiac and cerebrovascular events (MACCE). MACCE were
deﬁned as all-cause death, MI, TVR, and cerebrovascular accident
(CVA). MI was deﬁned as a clinical event with typical electrocar-
diographic or enzymatic changes [21]. We also investigated the
incidence of stent thrombosis, which was deﬁned according to the
criteria of the Academic Research Consortium [22]. TVR included
all incidences of PCI or coronary artery bypass grafting occurring
after the baseline procedure andwas diagnosed by recurrent symp-
toms, reinfarction, or objective report of signiﬁcant ischemia on
provocative testing. Clinical endpoints were documented by clini-
cal visits and standardized follow-up phone calls to the patients or
their families, followed by review ofmedical records. The diagnosis
of clinical endpoints was adjudicated by independent cardiologists
who were blinded to the ﬁndings of this registry. Left ventricular
ejection fraction was measured by transthoracic echocardiography
in all patients soon after hospitalization.
Continuous variables are presented as mean± standard devi-
ation (SD) and categorical variables as percentages. Categorical
variables were compared between groups using the 2 test or
Fisher’s exact test when appropriate, whereas continuous vari-
ables were compared with an unpaired t-test. Event-free survival
curves for cardiac eventswere constructed using the Kaplan–Meier
method, and statistical differences between curves were assessed
by the log-rank test. Logistic regression analyses were used to
investigate the univariate and multivariate predictors of events
during follow-up, adjusting for the differences in baseline patient
characteristics, lesion factors, procedural factors, and medications.
Multivariate models for MACCE included age and the important
variables with p<0.1 after univariate analysis. Data are presented
as hazard ratios and 95% conﬁdence intervals (CI).
Because the patients were not randomly assigned to stent
placement, a propensity score analysis was performed by using a
logistic regression model for BMS versus DES to adjust for differ-
ences in baseline characteristics. The covariates that were adjusted
for exposure to stent included age, sex, contrast volume, radiation
time, intra-aortic balloon pump (IABP), multivessel disease, trans-
radial intervention, right coronary artery (RCA) lesion, left anterior
descending artery (LAD) lesion, Type B2/C, intravascular ultra-
sound, stent length, peak creatine phosphokinase, warfarin use,
renin–angiotensin system inhibitor use, and beta-blocker use. The
C-statistic for the logistic regression model that was used to calcu-
late the propensity score matching for the two groups was 0.814.
Patients receiving BMS were then 1-to-1 matched to the patients
receiving DES on the propensity scores with the nearest available
pair-matching method. The maximum difference in the propensity
score allowed for a match was 0.013. The procedure yielded
101 well-matched pairs. After propensity score matching, the
ardiology 64 (2014) 377–383 379
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Table 1
Baseline characteristics.
BMS DES p-Value
(N=217) (N=184)
Age, years 64.2±13.6 66.4±11.7 0.08
Male, % 84.3 85.9 0.67
BMI, kg/m2 24.8±3.5 24.8±3.4 0.98
Diabetes mellitus, % 27.7 32.6 0.28
Insulin treated, % 0.9 2.2 0.30
Hypertension, % 57.6 54.9 0.59
Dyslipidemia, % 51.6 54.4 0.59
Current smoker, % 45.2 41.9 0.51
Family history, % 12.0 8.2 0.21
PAD, % 0.0 2.7 0.01
Prior MI, % 8.3 11.4 0.29
Prior CABG, % 0.9 2.2 0.30
Prior CHF, % 0.5 1.1 0.47
Prior CVA, % 5.5 4.9 0.78
Maintenance HD, % 0.9 1.1 0.87
LVEF <40% before PCI, % 3.7 4.9 0.55
Contrast volume, cc 188.3±49 204±56 <0.01
Radiation time, min 25.2±12 30.6±17 <0.01
IABP, % 7.8 2.2 0.01
MVD, % 19.4 32.6 <0.01
Staged PCI, % 9.7 21.7 <0.01
TVD, % 6.9 8.7 0.51
TRI, % 19.8 4.9 <0.01
Culprit lesion
LAD, % 34.6 44.6 0.04
LCx, % 6.0 6.0 0.99
RCA, % 59.5 48.9 0.03
Graft, % 0.0 0.54 0.28
Type B2/C 34.6 59.2 <0.01
Thrombus aspiration, % 74.7 76.6 0.64
Distal protection, % 9.7 9.8 0.97
IVUS, % 43.3 80.9 <0.01
Mean stent length, mm 19.9±5.2 23.3±5.4 <0.01
Final inﬂation pressure, atm 17.5±4.3 20.4±5.0 <0.01
Type of DES
SES 0 34.2 –
PES 0 13.6 –
ZES 0 16.3 –
BES 0 2.2 –
EES 0 33.7 –
Peak CPK, IU/l 3266±2369 2960±2062 0.01
Hb, g/dl 14.3±1.9 14.4±1.7 0.44
eGFR, ml/min/1.73m2 69.5±21 72.8±54 0.41
LDL/HDL ratio 2.66±1.0 2.71±0.9 0.56
Medication after admission
DAPT, % 99.2 100 0.52
Warfarin, % 2.3 8.2 <0.01
Statin, % 75.6 78.3 0.53
RAS inhibitor, % 65.9 76.6 0.04
Beta blocker, % 49.3 64.1 <0.01
Calcium channel blocker, % 7.8 10.9 0.29
BMS, bare-metal stent group; DES, drug-eluting stent group; BMI, body mass
index; PAD, peripheral artery disease; MI, myocardial infarction; CABG, coronary
artery bypass grafting; CHF, congestive heart failure; CVA, cerebrovascular acci-
dent; HD, hemodialysis; LVEF, left ventricular ejection fraction; PCI, percutaneous
coronary intervention; IABP, intra-aortic balloon pumping; MVD, multivessel dis-
ease; TVD, triple-vessel disease; TRI, trans-radial intervention; LAD, left anterior
descending artery; LCx, left circumﬂex artery; RCA, right coronary artery; IVUS,
intravascular ultrasound; SES, sirolimus-eluting stent; PES, paclitaxel-eluting stent;
BES, biolimus-eluting stent; ZES, zotarolimus-eluting stent; EES, everolimus-eluting
stent; CPK, creatine phosphokinase; eGFR, estimated glomerular ﬁltration rate;D. Abe et al. / Journal of C
aseline covariates were compared between the two stent groups.
ontinuous variables were compared with the paired t test, and
ategorical variables were compared with chi-square test or Fisher
xact test, as appropriate.
All the tests were two-sided, and a p-value of less than 0.05 was
onsidered statistically signiﬁcant. All the analyseswereperformed
sing SPSS software, version 15.0 for Windows (SPSS, Chicago, IL,
SA).
esults
We investigated clinical outcomes of 401 STEMI patients who
nderwent PCI with stent of ≥3.5mm in diameter. The mean age of
atients was 65.2±12.8 years, and 341 (85%) patients were men.
aseline characteristics of the two groups are shown in Table 1.
fter a mean follow-up period of 526 days, 14 (3.5%) patients
ied. There were no differences between the two groups in the
ncidences of in-hospital death (Group-B vs. Group-D: 1.84% vs.
.26%; p=0.37), all-cause death (4.61% vs. 4.35%; p=0.19), MI (0%
s. 0%), CVA (3.23% vs. 2.72%; p=0.76), stent thrombosis (1.38%
s. 0%; p=0.11), and MACCE (20.3% vs. 15.2%; p=0.19). TVR was
ower tendency in Group-D than Group-B (13.4% vs. 8.7%; p=0.14)
Table 2). Kaplan–Meier analysis showed no signiﬁcant difference
etween the twogroups in survival freeof all-causedeath (p=0.79),
r MACCE (p=0.15). TVR was lower in Group-D than Group-B
p=0.051) (Figs. 2–4).
Compared with patients who underwent PCI with BMS, those
ho underwent PCI with DES had no signiﬁcantly increased risk
f MACCE [odds ratio (OR): 0.70; 95% CI: 0.41–1.19; p=0.19] in
nivariate analysis. Other signiﬁcant predictors of MACCE in uni-
ariate analysis were age, insulin use, multivessel disease, IABP
se, RCA culprit, LAD culprit, and estimated glomerular ﬁltration
ate <60ml/min/1.73m2. After adjusting for these seven factors,
here were no signiﬁcant differences in MACCE between the two
roups (OR: 0.69; 95% CI: 0.40–1.23; p=0.21). Independent pre-
ictors of MACCE were multivessel disease (OR: 1.88; 95% CI:
.05–3.37; p=0.034) and IABP use (OR: 4.58; 95% CI: 1.72–12.1;
< 0.01) (Table 3).
After propensity score matching was performed for the entire
opulation, therewere 101matched pairs of patients. Although the
wo groups were well balanced in baseline characteristics, body
ass index and ﬁnal inﬂation pressure were higher in Group-D,
ncidence of peripheral artery disease, prior MI, and graft lesions
ere higher in Group-D than Group-B (Table 4).
There were no differences between the two groups in the
ncidences of in-hospital death (Group-B vs. Group-D: 1.0% vs.
.2%; p=0.10), all-cause death (3.1% vs. 6.2%; p=0.32), MI (0%
s. 0%), CVA (2.1% vs. 2.1%; p=1.0), stent thrombosis (1.0% vs.
%; p=0.32), and MACCE (19.6% vs. 16.5%; p=0.55). TVR was
ower tendency in Group-D than Group-B (15.5% vs. 8.2%; p=0.09)
Table 5). Kaplan–Meier analysis showed no signiﬁcant difference
etween the twogroups in survival freeof all-causedeath (p=0.13),
r MACCE (p=0.27). TVR was lower in Group-D than Group-B
p=0.049) (Figs. 5–7).
We also investigated possible differences between ﬁrst-
enerationDES (SES or paclitaxel-eluting stent: n=88) and second-
enerationDES (zotarolimus-eluting stent, EES, or biolimus-eluting
tent: n=96). Therewere no differences between the two groups in
he incidences of in-hospital death (ﬁrst-generation DES vs. second
enerationDES: 2.30% vs. 4.17%; p=0.37), all-cause death (5.75% vs.
.13%; p=0.39), MI (0% vs. 0%), CVA (2.30% vs. 3.13%; p=0.73), stent
hrombosis (0% vs. 0%), and MACCE (20.7% vs. 10.4%; p=0.054).
owever, the incidence of TVR was signiﬁcantly lower in the
econd-generation DES group (4.17%) than in the ﬁrst-generation
ES group (13.8%) (p=0.021).LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol;
DAPT, dual antiplatelet therapy; RAS, renin–angiotensin system.
Discussion
The main ﬁnding of the present study of patients with STEMI
requiring large coronary stents (≥3.5mm) was that during the
median follow-up period, all-cause death, MI, CVA, MACCE, and
ST were not signiﬁcantly different between patients receiving BMS
and those receiving DES. However, DES might have a beneﬁt for
preventing TVR. The likelihood of a beneﬁt from DES is relatively
380 D. Abe et al. / Journal of Cardiology 64 (2014) 377–383
Table 2
Clinical outcomes.
BMS DES p-Value
(N=217) (N=184)
In-hospital death, % 1.84 3.26 0.37
MACCE, % 20.3 15.2 0.19
All cause death, % 4.61 4.35 0.90
Myocardial infarction, % 0 0
TVR, % 13.4 8.7 0.14
CVA, % 3.23 2.72 0.76
Stent thrombosis, % 1.38 0 0.11
Acute (n) 1 0 0.36
Sub-acute (n) 1 0 0.36
Late (n) 1 0 0.36
Very late (n) 0 0 –
BMS, bare-metal stent group; DES, drug-eluting stent group; MACCE, major adverse
cardiac and cerebrovascular events; TVR, target vessel revascularization; CVA, cere-
brovascular accident.
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Fig. 4. Kaplan–Meier curves describing survival free of target-vessel revasculariza-ig. 2. Kaplan–Meier curves describing survival free of major cardiac and cere-
rovascular events (MACCE). The black line indicates the bare-metal stent group
BMS), and the dashed line indicates the drug-eluting stent group (DES).
mall in patients with occlusions in large coronary arteries because
he rate of restenosis is low and the risk of adverse cardiac events
ue to late stent thrombosis may be greater than the risk among
atients with small-vessel stents [6,7,23]. Steinberg et al. reported
hat implantation of DES in large coronary arteries confers no addi-
ional beneﬁt compared with BMS, and the two approaches are
ssociated with equally favorable clinical outcomes at 1 year [18].
ig. 3. Kaplan–Meier curves describing survival free of all-cause death. The black
ine indicates the bare-metal stent group (BMS), and the dashed line indicates the
rug-eluting stent group (DES).tion (TVR). Theblack line indicates thebare-metal stent group (BMS), and thedashed
line indicates the drug-eluting stent group (DES).
We also could not prove an advantage of DES over BMS in large
coronary arteries for preventing hard endpoints in the STEMI set-
ting.
Although Shugman et al. reported that BMS deployment in
STEMI patients with infarct-related arteries of ≥3.5mm in diam-
eter was associated with low rates of TVR [24], we reported the
beneﬁt of DES for preventing TVR. This report showed an inci-
dence of death at 1 year of 4.4%, which is similar to our result
(4.6%). However, the incidence of TVR was 2.2% in their report,
whereas it was 13.4% in the present study. This might be related
to the inclusion of relatively large numbers of patients at high
risk for events from an all-inclusive clinical setting rather than
a randomized controlled trial. Also, follow-up was longer in our
study than in previous studies. Recently, a comprehensive network
meta-analysis that included 22 trials with 12,453 STEMI patients
demonstrated that EES were associated with signiﬁcantly lower
rates of 1-year cardiac death/MI, MI, deﬁnite stent thrombosis, and
deﬁnite/probable stent thrombosis than were BMS, and the reduc-
tion in cardiacdeath/MIand in stent thrombosiswithEEScompared
to BMS was already apparent at 30 days and was maintained for
up to 2 years of follow-up [25]. Sabate et al. reported that the use
of EES compared with BMS in the setting of STEMI did not lower
the patient-oriented endpoints, but at the stent level, rates of both
target lesion revascularization and stent thrombosis were reduced
[26]. However, these studies did not show an additional beneﬁt of
DES use in large coronary arteries compared with BMS. It is impor-
tant to note that our study indicated the usefulness of BMS in the
STEMI settingwith large coronary arteries. Discontinuationof dual-
antiplatelet therapymight be a relief for thepatients receivingBMS,
Table 3
Cox logistic regression analysis.
Independent predictors of MACCE OR 95% CI p-Value
DES (vs. BMS) 0.69 0.40–1.23 0.21
Age 1.02 0.99–1.05 0.052
Insulin use 2.70 0.49–14.8 0.25
Multivessel disease 1.88 1.05–3.37 0.034
IABP use 4.58 1.72–12.1 <0.01
RCA culprit 1.18 0.37–3.73 0.78
LAD culprit 0.73 0.21–2.46 0.61
eGFR ≤60ml/min/1.73m2 1.60 0.89–2.86 0.11
MACCE, major adverse cardiac and cerebrovascular events; DES, drug-eluting stent
group; BMS, bare-metal stent group; IABP, intra-aortic balloon pumping; OR, odds
ratio; CI, conﬁdence interval; RCA, right coronary artery; LAD, left anterior descen-
ding artery; eGFR, estimated glomerular ﬁltration rate.
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Table 4
Baseline characteristics after propensity score matched analysis.
BMS DES p-Value
(N=101) (N=101)
Age, years 65.0±14.4 64.9±12.5 0.95
Male, % 87.6 83.5 0.42
BMI, kg/m2 24.5±2.8 24.9±3.3 0.02
Diabetes mellitus, % 24.7 36.0 0.10
Insulin treated, % 1.03 3.09 0.32
Hypertension, % 62.9 55.6 0.30
Dyslipidemia, % 52.6 54.6 0.78
Current smoker, % 46.4 42.3 0.57
Family history, % 10.3 12.4 0.67
PAD, % 0.0 4.1 0.04
Prior MI, % 7.2 18.6 0.03
Prior CABG, % 2.1 4.1 0.42
Prior CHF, % 1.0 1.0 1.00
Prior CVA, % 8.2 6.2 0.57
Maintenance HD, % 2.1 2.1 1.00
LVEF <40% before PCI, % 4.1 5.2 0.74
Contrast volume, cc 201.5±56 193.9±48 0.29
Radiation time, min 26.9±14 27.8±15 0.64
IABP, % 4.1 3.1 0.71
MVD, % 21.6 25.8 0.48
Staged PCI, % 11.3 12.4 0.81
TVD, % 7.2 9.3 0.59
TRI, % 13.4 7.2 0.18
Culprit lesion
LAD, % 42.3 32.0 0.12
LCx, % 6.2 4.1 0.53
RCA, % 51.5 62.9 0.11
Graft, % 0.0 1.0 0.03
Type B2/C 49.5 48.5 0.87
Thrombus aspiration, % 77.3 72.2 0.39
Distal protection, % 9.3 9.3 1.00
IVUS, % 67.0 67.0 1.00
Mean stent length, mm 21.3±5.7 21.4±5.1 0.81
Final inﬂation pressure, atm 17.6±4.6 19.4±4.8 <0.01
Type of DES
SES 0 29.9 –
PES 0 18.6 –
ZES 0 19.6 –
BES 0 1.0 –
EES 0 30.9 –
Peak CPK, IU/l 2886±2226 2731±2034 0.58
Hb, g/dl 14.2±1.9 14.4±1.8 0.55
eGFR, ml/min/1.73m2 68.6±21.5 76.4±72.7 0.32
LDL/HDL ratio 2.8±1.0 2.7±0.9 0.71
Medication after admission
DAPT, % 47.4 58.8 0.11
Warfarin, % 5.2 5.2 1.0
Statin, % 64.9 66.0 0.89
RAS inhibitor, % 75.3 71.1 0.55
Beta blocker, % 58.8 54.6 0.54
Calcium channel blocker, % 12.4 13.4 0.83
BMS, bare-metal stent group; DES, drug-eluting stent group; BMI, body mass
index; PAD, peripheral artery disease; MI, myocardial infarction; CABG, coronary
artery bypass grafting; CHF, congestive heart failure; CVA, cerebrovascular acci-
dent; HD, hemodialysis; LVEF, left ventricular ejection fraction; PCI, percutaneous
coronary intervention; IABP, intra-aortic balloon pumping; MVD, multivessel dis-
ease; TVD, triple-vessel disease; TRI, trans-radial intervention; LAD, left anterior
descending artery; LCx, left circumﬂex artery; RCA, right coronary artery; IVUS,
intravascular ultrasound; SES, sirolimus-eluting stent; PES, paclitaxel-eluting stent;
BES, biolimus-eluting stent; ZES, zotarolimus-eluting stent; EES, everolimus-eluting
stent; CPK, creatine phosphokinase; Hb, hemoglobin; eGFR, estimated glomerular
ﬁ
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Table 5
Clinical outcomes after propensity score matched analysis.
BMS DES p-Value
(N=101) (N=101)
In-hospital death, % 1.0 5.2 0.10
MACCE, % 19.6 16.5 0.55
All cause death, % 3.1 6.2 0.32
Myocardial infarction, % 0 0 –
TVR, % 15.5 8.2 0.09
CVA, % 2.1 2.1 1.0
Stent thrombosis, % 1.0 0.0 0.32
Acute (n) 1 0 0.32
Sub-acute (n) 0 0 –
Late (n) 0 0 –
Very late (n) 0 0 –
the effects of treatment. All the components of the primary end-
points, including in-hospital death and MACCE, are less subject to
observation bias. The rates of use of statins and beta-blockers were
low in the registry, unlike that in current practice. Finally, it shouldltration rate; LDL, low-density lipoprotein cholesterol; HDL, high-density lipopro-
ein cholesterol; DAPT, dual antiplatelet therapy; RAS, renin–angiotensin system.
orwhom theirmedical background, such as the presence ofmalig-
ancy or a bleeding disorder, is unknown in the emergency setting
t the time of STEMI.
Gomez et al. reported in their sub-analysis of the EXAMINATION
tudy that patients with STEMI and proximal LAD lesions treated
ith EES have better outcomes than those treated with BMS at
year [27]. We also investigated lesion sites, but there was no sig-
iﬁcant difference in MACCE for LAD lesions (Group D vs. Group B:BMS, bare-metal stent group; DES, drug-eluting stent group; MACCE, major adverse
cardiac and cerebrovascular events; TVR, target vessel revascularization; CVA, cere-
brovascular accident.
12.2% vs. 10.7%, p=0.77), whereas there was a trend toward a more
favorableoutcome forRCA lesions in theDESgroup (16.7%vs. 27.1%,
p=0.07). Brodie et al. reported that DES was the independent pre-
dictor of very late stent thrombosis compared with BMS (hazard
ratio: 3.73, 95% CI: 1.81–7.88) in a Western population [28]. Our
study suggests that the incidence of stent thrombosis was low in
patients with large vessels in both groups, but additional follow-up
would be needed to further investigate late-term events.
We also compared ﬁrst-generationDESwith second-generation
DES. There were no differences in the incidences of in-hospital
death, all-cause death, MI, CVA, stent thrombosis, and MACCE
between the ﬁrst-generation and second-generation groups. How-
ever, the incidence of TVR was lower in the second-generation
group than in the ﬁrst-generation group. Although we could not
prove an advantage of second-generation DES over that of the ﬁrst-
generationDES in termsofMACCE, therewas a trend towardamore
favorable outcome with the second-generation DES. This result
might be inﬂuenced by lack of required number of patients, and
therefore, additional follow-up will be needed in a larger popula-
tion.
Several limitations in the design of the ICAS registry should
be mentioned. This retrospective, nonrandomized study included
a relatively small sample size. In observational studies, outcomes
may reﬂect a lack of comparability in treatment groups rather thanFig. 5. Kaplan–Meier curves describing survival free of major cardiac and cere-
brovascular events (MACCE) after propensity score matching analysis. The black
line indicates the bare-metal stent group (BMS), and the dashed line indicates the
drug-eluting stent group (DES).
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Fig. 6. Kaplan–Meier curves describing survival free of all-cause death after propen-
sity score matching analysis. The black line indicates the bare-metal stent group
(BMS), and the dashed line indicates the drug-eluting stent group (DES).
Fig. 7. Kaplan–Meier curves describing survival free of target-vessel revasculariza-
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[23] PﬁstererM,Brunner-LaRoccaHP,BuserPT,RickenbacherP,HunzikerP,Muellerion (TVR) after propensity score matching analysis. The black line indicates the
are-metal stent group (BMS), and the dashed line indicates the drug-eluting stent
roup (DES).
e noted that the ﬁndings of this study do not relate to patients
ith smaller coronary arteries.
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